Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To present the most recent and comprehensive systematic review and meta-analysis assessing the predictive value of prognostic nutritional index (PNI) for the long-term outcomes of elderly patients with fractures.
Methods: We systematically searched PubMed, Cochrane, Embase and Web of Science up to July, 2025 for studies assessing the predictive value of PNI for the long-term prognosis of elderly patients with fractures. The primary outcome measured was mortality. Odds ratios (ORs) and 95% confidence intervals (CIs) were used for data pooling. Additionally, sensitivity and subgroup analyzes were performed to assess the stability of the results and identify potential sources of heterogeneity. All analyzes were performed using Review Manger 5.4 and STATA 15.1.
Results: Eight studies encompassing 11,576 elderly individuals were included for meta-analysis. The meta-analysis demonstrated that mortality was notably lower in individuals with high PNI compared to those with low PNI (OR: 0.75; 95% CI: 0.66, 0.85; < 0.0001). Subgroup analysis of mortality based on study design and PNI cut-off showed that the predictive value of PNI for mortality remained significant in prospective studies and those with a cut-off value ≥40. However, this association was not observed in retrospective studies or those with a cut-off below 40.
Conclusion: PNI can effectively predict the long-term mortality in elderly individuals with fractures. Considering the limitations of this article, future large-scale, multicenter prospective cohort studies are still required to evaluate the prognostic value of PNI in senior patients with fractures and its influencing factors.
Systematic Review Registration: PROSPERO, identifier CRD420251047385.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375473 | PMC |
| http://dx.doi.org/10.3389/fnut.2025.1631128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IGLV3-21-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
Haematologica
September 2025
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel.
We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors.
View Article and Find Full Text PDFAge-related differences in donor selection priorities for allogeneic hematopoietic transplantation.
Haematologica
September 2025
Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke.
Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes among human leukocyte antigen (HLA)-matched related donors (M-RDs, n=4,106), HLA 1-antigen-mismatched related donors (1MM-RDs, n=592), HLA 2-3-antigen-mismatched related donors (23MM-RDs, n=882), HLA-matched unrelated donors (M-UDs, n=3,927), HLA 1-locus-mismatched unrelated donors (1MM-UDs, n=2,474), and unrelated cord blood units (U-CBs, n=5,867) between patients aged.
View Article and Find Full Text PDFAntibiotic Therapy for Pyelonephritis in the Emergency Department.
Emerg Med Australas
October 2025
Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.
View Article and Find Full Text PDFIn-Flight Deterioration Occurs Early in Aeromedical Trauma Patients.
Emerg Med Australas
October 2025
Australian Centre for Health Services Innovation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.
Reliably defining the risk of adverse in-flight events in aeromedical trauma patients could enable more informed pre-departure treatment and guide central asset allocation to achieve better system-level outcomes. Unfortunately, the current literature base specifically examining the in-flight period is sparse. Flight duration is often considered a proxy for the risk of in-flight deterioration; however, there is limited data to support this commonly held assumption.
View Article and Find Full Text PDFImpact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
Diabetes Obes Metab
September 2025
Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
Aims: Chronic ocular diseases such as age-related macular degeneration (AMD) are leading causes of vision loss in older adults. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) are widely prescribed in the management of type 2 diabetes mellitus (T2DM), their effects on ocular disease risk remain largely unknown.
Materials And Methods: This retrospective cohort study evaluated the association between SGLT2i use and the risk of AMD and other age-related ocular conditions in adults aged ≥60 with T2DM, using a target trial emulation framework based on the TriNetX global health research network (2013-2025).